1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Zhejiang CONBA Pharmaceutical Co.,Ltd.

Zhejiang CONBA Pharmaceutical Co.,Ltd.

600572.SS
Zhejiang CONBA Pharmaceutical Co.,Ltd.CN flagShanghai Stock Exchange
4.08
CNY
-0.05
- -
10.36BMarket Cap
Zhejiang CONBA Pharmaceutical Co.,Ltd.
600572.SS
(Shanghai Stock Exchange)

Recent

price

4.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.14
1.26
1.52
1.43
1.73
2.29
2.46
2.08
2.67
2.55
2.35
2.54
2.35
2.62
2.62
2.59
2.54
Revenue per Share
0.12
0.16
0.16
0.2
0.27
0.19
0.18
0.28
0.31
-0.13
0.18
0.78
0.14
0.23
0.25
0.19
0.24
Basic EPS, GAAP
- -
0.05
- -
-0.12
0.09
0.23
0.3
0.17
0.06
0.25
0.31
0.12
0.34
0.27
0.29
0.32
-0.1
Free Cash Flow per Basic Share
0.05
0.04
0.09
0.08
0.11
0.16
0.12
0.13
0.18
0.2
0.06
0.03
0.19
0.16
0.21
0.15
0.15
Dividend per Share
0.44
0.69
0.76
0.81
1
1.28
1.64
1.78
1.84
1.53
1.79
2.48
2.4
2.41
2.5
2.43
2.44
Book Value per Share
0.94
0.82
1.11
1.01
0.94
1.25
1.26
1.76
1.7
1.62
1.91
2.73
2.64
2.64
2.55
2.64
2.51
Tangible Book Value per Share
1,657
1,795
1,795
2,047
2,071
2,318
2,450
2,540
2,630
2,659
2,518
2,586
2,558
2,572
2,490
2,497
2,525
Basic Weighted Avg Shares
1,892
2,260
2,734
2,924
3,582
5,302
6,020
5,294
7,018
6,768
5,909
6,568
6,000
6,733
6,515
6,473
6,425
Sales/Revenue/Turnover
10.47
12.73
12.87
14.54
18.39
16.57
12.71
19.26
16.63
15.39
12.48
13.39
13.09
12.55
10.96
9.64
9.98
Operating Margin (%)
68
75
88
100
128
174
230
217
241
261
266
287
277
324
345
345
- -
Depreciation Expense
195
294
296
417
552
440
441
711
815
-346
453
2,017
358
592
622
474
594
Net Income, GAAP
12.53
12.75
16.43
17.89
14.53
17.49
24.39
18.54
20.55
- -
28.27
15.48
22.02
12.11
15.59
23.81
15.62
Effective Tax Rate (%)
10.31
12.99
10.82
14.27
15.42
8.31
7.33
13.43
11.62
-5.11
7.67
30.72
5.97
8.79
9.55
7.33
9.24
Profit Margin (%)
753
989
1,334
1,138
332
710
1,124
2,336
1,258
502
882
2,298
2,606
2,603
1,902
2,120
1,933
Working Capital
35
604
653
654
904
532
1,134
1,110
1,258
511
507
13
334
306
120
41
73
LT Debt
1,749
1,686
2,441
2,592
3,370
4,565
4,488
5,844
5,856
4,943
5,349
7,635
7,324
7,350
6,913
7,152
6,915
Total Equity
9.19
10.52
9.13
9.24
12.62
11.83
8.52
11.75
11.51
- -
6.83
8.72
6.86
8.69
7.6
6.36
7.25
Return on Invested Capital (%)
16.14
16.27
11.37
14.8
12.28
9.52
9.31
12.02
12.82
- -
6.28
25.24
3.66
7.06
8.45
7.01
8.62
Return on Capital (%)
29.75
29.93
22.77
27.58
29.62
17.49
12.63
16.68
17.43
-7.77
10.59
36.94
5.7
9.57
10.02
7.72
9.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
304
166
229
LT Borrowings
118
108
72
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,583
2,584
2,585
Market Capitalization
11,986
11,313
11,061

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
4,419
4,518
4,404
Cash, Cash Equivalents & STI
1,322
771
873
Accounts Receivable, Net
1,147
1,338
1,351
Inventories
1,266
1,202
1,154
Total Current Liabilities
2,516
2,384
2,471
Payables & Accruals
- -
- -
- -
ST Debt
304
166
229
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.79%
7.3%
3.46%
Free Cash Flow
37.19%
22.55%
10.17%
Net Income, GAAP
1.19%
61.88%
-23.79%
Sales/Revenue/Turnover
2.86%
2.17%
-0.64%
Total Cash Common Dividend
39.52%
83.98%
-26.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,824
1,624
1,465
1,602
6,515
2025
1,685
1,674
1,498
- -
6,473
2026
1,906
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
- -
- -
- -
0.25
2025
0.08
- -
- -
- -
0.19
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -
Similar Companies
NanJing Pharmaceutical Company Limited (600713.SS)
Astellas Pharma Inc. (4503.T)
PharmGen Science, Inc. (004720.KS)
Amgen Inc. (AMGN)
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (600613.SS)
Business
Zhejiang CONBA Pharmaceutical Co., Ltd. (600572.SS) engages in the research, development, manufacturing, and sales of traditional Chinese medicines, modern phytomedicines, chemical drugs, and active pharmaceutical ingredients primarily in China. The company offers an extensive range of products including Chinese herbal decoction pieces and patent medicines; chemical pharmaceutical preparations and raw materials; biological products and medical devices; and diverse dosage forms such as tablets, capsules, pills, dripping pills, granules, powders, injections, freeze-dried powder injections, oral liquids, syrups, nasal drops, eye drops, ear drops, and ointments, targeting therapeutic areas like cardiovascular and cerebrovascular diseases, urinary system disorders, digestive conditions, respiratory illnesses, endocrine and nervous system ailments, and anti-infectives. Founded in 1969 as Lanxi Yunshan Pharmaceutical Factory and renamed in 1999, it is headquartered at 568 Binkang Road, Binjiang Sci & Tech Economic Park, Hangzhou, China, with approximately 8,411 employees and operations focused on the domestic market; it functions as a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. Notable branded products encompass Anlevolecon purean tablets and capsules; Tianbaoning ginkgo biloba preparations; Kangenbei enteritis treatments; Jinaokang omeprazole products; Jin Di compound houttuynia cordata; Jinkang Speed acetylcysteine effervescent tablets; and Zhixinping musk xixin drop pills, alongside health foods under Baozhilin, Yangyingtang, and other labels. In recent developments, its subsidiary Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd. entered a strategic supply partnership with EVA Pharma in June 2025 at CPHI China to enhance pharmaceutical supply chain resilience and accessibility in emerging markets, particularly the Middle East and Africa; the company also secured registration for Qinghouyan lozenges in May 2025 and reported a 12.3% year-over-year decline in Q1 2025 net profit.